Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:19:45 2024-05-03 pm EDT			5-day change	1st Jan Change
233.4 ^USD	+8.04%		+20.07%	+0.32%

Apr. 22	BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective	MT
Apr. 22	BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target	MT

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

April 23, 2024 at 08:01 am EDT

CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets.

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

The webcast will be available approximately two hours after the live webcast.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

Source: Madrigal Pharmaceuticals, Inc.

2024 GlobeNewswire, Inc., source Press Releases

Latest news about Madrigal Pharmaceuticals, Inc.

BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective	Apr. 22	MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target	Apr. 22	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing	Apr. 11	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing	Apr. 11	MT
Madrigal Pharmaceuticals Says Rezdiffra Available in US	Apr. 09	MT
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis	Apr. 09	CI
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing	Apr. 04	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing	Apr. 04	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing	Apr. 04	MT
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating	Mar. 20	MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	Mar. 19	MT
Madrigal Pharmaceuticals Prices $600 Million Public Offering	Mar. 19	MT
Madrigal Pharmaceuticals Starts $500 Million Public Offering	Mar. 18	MT
Madrigal plans $500 million fund raising to prepare for NASH drug launch	Mar. 18	RE
Madrigal commences $500 million public offering of common stock	Mar. 18	RE
North American Morning Briefing : Investors -2-	Mar. 18	DJ
TD Cowen Adjusts Madrigal Pharmaceuticals' Price Target to $390 From $349, Maintains Outperform Rating	Mar. 15	MT
Madrigal Pharmaceuticals Gets Added Boost with Rezdiffra Nod From FDA, B. Riley Says	Mar. 15	MT
Citigroup Adjusts Madrigal Pharmaceuticals' Price Target to $389 From $382, Maintains Buy Rating	Mar. 15	MT
Global markets live: Adobe, Ulta Beauty, Intel, Walt Disney, McDonald's...	Mar. 15
JMP Securities Adjusts Price Target on Madrigal Pharmaceuticals to $397 From $351, Maintains Market Outperform Rating	Mar. 15	MT
Old demons return as tech takes a dive	Mar. 15
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $375 From $320, Maintains Outperform Rating	Mar. 15	MT
H.C. Wainwright Adjusts Price Target on Madrigal Pharmaceuticals to $425 From $405, Maintains Buy Rating	Mar. 15	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Mar. 15	MT

Chart Madrigal Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

216 USD

Average target price

377.1 USD

Spread / Average Target

+74.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MADRIGAL PHARMACEUTICALS, INC.	+0.32%	4.6B
VERTEX PHARMACEUTICALS INCORPORATED	-1.18%	103B
REGENERON PHARMACEUTICALS, INC.	+8.34%	101B
ARGENX SE	+4.40%	23.07B
BIONTECH SE	-12.13%	22.23B
GENMAB A/S	-4.36%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.73%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.63%	14.07B
SAREPTA THERAPEUTICS, INC.	+38.75%	12.35B

Bio Therapeutic Drugs